Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry.
about
A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serumImpact of immunization technology and assay application on antibody performance--a systematic comparative evaluationProteogenomic convergence for understanding cancer pathways and networks.Quantitative peptidomic analysis by a newly developed one-step direct transfer technology without depletion of major blood proteins: its potential utility for monitoring of pathophysiological status in pregnancy-induced hypertension.Combining ultracentrifugation and peptide termini group-specific immunoprecipitation for multiplex plasma protein analysis.An assessment of current bioinformatic solutions for analyzing LC-MS data acquired by selected reaction monitoring technology.Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1High-affinity recombinant antibody fragments (Fabs) can be applied in peptide enrichment immuno-MRM assays.Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification.A targeted proteomics-based pipeline for verification of biomarkers in plasmaOncoproteomics: Trials and tribulations.Regulatory control or oxidative damage? Proteomic approaches to interrogate the role of cysteine oxidation status in biological processes.Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry Enables Multiplex, Quantitative Pharmacodynamic Studies of Phospho-Signaling.Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics.Contributions of mass spectrometry-based proteomics to defining cellular mechanisms and diagnostic markers for systemic lupus erythematosus.Multiplexed quantification of estrogen receptor and HER2/Neu in tissue and cell lysates by peptide immunoaffinity enrichment mass spectrometry.Global stability of plasma proteomes for mass spectrometry-based analyses.Sequential multiplexed analyte quantification using peptide immunoaffinity enrichment coupled to mass spectrometryInterlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasmaTryptic peptide screening for primary immunodeficiency disease by LC/MS-MS.Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptidesImmunocapture strategies in translational proteomics.The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification.Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MSTargeted quantification of low ng/mL level proteins in human serum without immunoaffinity depletionAntibody-Coupled Magnetic Beads Can Be Reused in Immuno-MRM Assays To Reduce Cost and Extend Antibody SupplyCommercially available antibodies can be applied in quantitative multiplexed peptide immunoaffinity enrichment targeted mass spectrometry assays.Long-gradient separations coupled with selected reaction monitoring for highly sensitive, large scale targeted protein quantification in a single analysis.Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma.Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins.Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometryTargeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach.Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics.The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science.Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies.Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins.Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present.Pre-analytical and analytical variability in absolute quantitative MRM-based plasma proteomic studies.Hold or fold--proteins in advanced heart failure and myocardial recovery.Current trends in magnetic particle enrichment for mass spectrometry-based analysis of cardiovascular protein biomarkers.
P2860
Q24307894-240CDA06-4B07-4BF8-9D56-A62BE140AC9CQ28741074-300DCD47-BCCF-4D5C-892C-222E62F90709Q33792433-FE195809-F27C-4D30-945B-3D51567CA6B5Q33918651-C1C30868-841D-4E0A-91E2-641D1D687F3BQ34242987-E689B500-9BC2-4DA7-B99D-49E11E8CE098Q34265969-B8E2E29A-76F2-4D2B-9971-763BB55AFF3BQ35053898-2BC24512-6416-4EB4-B1AA-BCFCF53273FBQ35102677-8F502AF0-76D8-4FF8-934E-CA85DC9D0B64Q35264312-1738C0CD-D352-47A8-AD5C-ADD8B0C696ACQ35596338-5083E45A-6D93-4ED9-861C-24B6BA24E02FQ35827653-8A9063A5-207C-4AC4-A29B-D31836274597Q35878798-0BEFD054-D413-4CD1-8FA3-0E36A3A9BDA2Q35926217-B128296F-3AF8-4C6E-960F-5D0A1FFD2324Q36031629-34BAB69C-2268-49DE-BE49-2918C2B80CFDQ36084958-5200F40F-B682-47EC-AEB9-C1DD34474E97Q36163327-9E014CA3-F541-4A53-AAA3-5E6BF024C3CFQ36208968-5F53C860-F27E-4180-9CA8-0CC0F6F1F869Q36208981-354164E8-6F34-4C00-B23D-BC8E4166A6B2Q36209072-FC7852A4-0DFD-4B80-87E1-67530F37BB48Q36372683-B3160A71-A777-4726-892B-2205636CB396Q36386913-31A84EF0-4633-4737-A37C-BC45B1F66AAEQ36519000-F1F65ADE-3BB5-4E55-9E87-BF25429E1D2AQ36771005-FA4A4A6E-DE31-4963-898B-A4F9E9CFA1BCQ36977460-12212BAD-4B3E-46C4-A369-18AE0347A7B5Q37069906-13142F36-7DD1-4EBF-930E-1FA64B1E8347Q37244478-E93CA27C-2246-4C6A-9537-5D526BFCE7B0Q37258824-1FA9C2A0-AF0F-4947-859E-CA3DF8879D2FQ37341145-6D3F1445-4E0B-426D-8DC2-B08F786C527DQ37394942-73D2B8EE-93BC-4710-809C-297966B0C605Q37580083-043969CE-FE78-4EF2-857F-BD39D92FD46BQ37618631-7B4D8F63-51DC-4B5A-86C0-40B21E35DDC8Q37623655-4EC39608-A216-419C-A2F6-81115ABEF7D7Q37680069-9224F7C9-19A3-4982-98FD-2EDACDC9FA1BQ37720601-14BEE390-C9FF-454D-83D6-1E83D806D3C0Q37972865-43A2987C-A08B-4077-B28F-10B137529DA4Q38009277-0CCEBBA3-E6F1-4B63-BD6F-EB5AB4C90FF3Q38024637-BE427F6D-CC13-44C8-A853-F01342ED359CQ38164428-C4F9793A-019E-4153-80CD-025082A7E43DQ38261514-CA7663BD-0AB7-49B3-B149-7439014E77BBQ38364469-10EDE461-ADDA-46AC-8836-76AC318ABBB5
P2860
Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Evaluation of large scale quan ...... inity-based mass spectrometry.
@ast
Evaluation of large scale quan ...... inity-based mass spectrometry.
@en
Evaluation of large scale quan ...... inity-based mass spectrometry.
@nl
type
label
Evaluation of large scale quan ...... inity-based mass spectrometry.
@ast
Evaluation of large scale quan ...... inity-based mass spectrometry.
@en
Evaluation of large scale quan ...... inity-based mass spectrometry.
@nl
prefLabel
Evaluation of large scale quan ...... inity-based mass spectrometry.
@ast
Evaluation of large scale quan ...... inity-based mass spectrometry.
@en
Evaluation of large scale quan ...... inity-based mass spectrometry.
@nl
P2093
P2860
P356
P1476
Evaluation of large scale quan ...... inity-based mass spectrometry.
@en
P2093
Amanda G Paulovich
ChenWei Lin
Jeffrey R Whiteaker
Matthew E Pope
Michael Burgess
Morteza Razavi
N Leigh Anderson
Steven A Carr
P2860
P304
M110.005645
P356
10.1074/MCP.M110.005645
P577
2011-01-18T00:00:00Z